BiotechTube
Advesya

Advesya

Paris, France· Est.
advesya.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Advesya is a private, clinical-stage biotech leveraging a novel target, IL-1RAP, to develop therapies for cancer and autoimmune diseases. Founded in 2020 as a spin-out from the French Blood Institute (EFS), the company has rapidly advanced two core programs: an ADC (ADV-101) and a CAR T-cell therapy (CCTx-001). Backed by investor Jeito and led by an experienced team, Advesya aims to address critical unmet medical needs by inhibiting a key pathway in chronic inflammation and oncology.

OncologyAutoimmune Diseases

Technology Platform

Platform focused on targeting the IL-1RAP antigen, a shared co-receptor for IL-1 family cytokines, using customized therapeutic modalities including antibody-drug conjugates (ADCs) and CAR T-cell therapies.

Opportunities

The IL-1RAP target offers a novel approach to treating a wide range of cancers and autoimmune diseases with high unmet need, supported by its differential expression on diseased versus healthy tissue.
Success in one therapeutic modality (e.g., ADC) could rapidly validate the target and create value for the other (CAR T).
The growing markets for targeted biologics, ADCs, and cell therapies present significant commercial potential.

Risk Factors

The novel IL-1RAP target is unproven in clinical settings, posing a high risk of clinical failure.
The company is pre-revenue and dependent on external financing in a challenging capital environment.
It faces intense competition in both the ADC and CAR T-cell therapy spaces from larger, more established biopharma companies.

Competitive Landscape

Advesya competes in the crowded fields of ADC and CAR T-cell therapy, where numerous companies are developing targeted oncology drugs. Its primary differentiation is the novel IL-1RAP target. In autoimmune diseases, it will compete against approved IL-1 pathway inhibitors (e.g., canakinumab) and other cytokine-targeting therapies, where it must demonstrate superior efficacy or safety.

More companies in Immunotherapy / Immuno-Oncology →More companies in France →